信立泰(002294.SZ)：SAL0139获得临床试验批准通知书

Core Viewpoint - The company, Xinlitai (002294.SZ), has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0139, aimed at treating hyperlipidemia [1] Group 1 - The drug SAL0139 is a self-developed innovative small molecule medication [1] - The approval allows the company to commence clinical trials for the treatment of hyperlipidemia [1]